Mycophenolate mofetil‐induced peripheral neuropathy in the treatment of membranous glomerulonephropathy: A case report

Autor: Minoo Moghimi, Zahra Nekoukar, Farhad Gholami

Publikováno v: Clinical Case Reports, Vol 9, Iss 12, Pp n/a-n/a (2021)

Abstract Mycophenolate mofetil (MMF) as an immunosuppressive agent is widely used in the management of Membranous Glomerulonephropathy (MGN). In this report, we described a 66‐year‐old male MGN case treated with MMF and revealed acquired sensory�

Externí odkaz: https://doaj.org/article/18392f45ad8b415a831e754eef1022f9

Mycophenolate mofetil‐induced peripheral neuropathy in the treatment of membranous glomerulonephropathy: A case report

Autor: Zahra Nekoukar, ّFarhad Gholami, Minoo Moghimi

Publikováno v: Clinical Case Reports
Clinical Case Reports, Vol 9, Iss 12, Pp n/a-n/a (2021)

Mycophenolate mofetil (MMF) as an immunosuppressive agent is widely used in the management of Membranous Glomerulonephropathy (MGN). In this report, we described a 66‐year‐old male MGN case treated with MMF and revealed acquired sensory‐motor a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::69e53ce7cb7a2e6427715d07fb16dfd2
https://doi.org/10.1002/ccr3.5161

Incidence, management, and outcomes of autoimmune nephropathies following alemtuzumab treatment in patients with multiple sclerosis

Autor: Daniel Wynn, David Margolin, Richard G Phelps, Glen S. Markowitz, Alasdair Coles, Mario Habek, Claudio E Rodriguez, Darren P Baker, Hans-Peter Hartung, Jonathan A. Winston, Eva Havrdova

Publikováno v: Multiple Sclerosis (Houndmills, Basingstoke, England)
Phelps, R, Winston, J A, Wynn, D, Habek, M, Hartung, H-P, Havrdová, E K, Markowitz, G S, Margolin, D H, Rodriguez, C E, Baker, D P & Coles, A J 2019, ' Incidence, management, and outcomes of autoimmune nephropathies following alemtuzumab treatment in patients with multiple sclerosis ', Multiple Sclerosis Journal, pp. 1352458519841829 . https://doi.org/10.1177/1352458519841829

Background: Autoimmune disorders including nephropathies have been reported more frequently in alemtuzumab-treated multiple sclerosis (MS) patients than in the general population. Objective: Describe instances of autoimmune nephropathy in alemtuzumab

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::28cbb60d65292860c592c902ee0dbb1c
https://pubmed.ncbi.nlm.nih.gov/31368417

MicroRNAs as Biomarkers for Nephrotic Syndrome

Autor: Shinji Kitamura, Kenji Tsuji, Jun Wada

Publikováno v: International Journal of Molecular Sciences
International Journal of Molecular Sciences, Vol 22, Iss 88, p 88 (2021)

Nephrotic syndrome represents the clinical situation characterized by presence of massive proteinuria and low serum protein caused by a variety of diseases, including minimal change nephrotic syndrome (MCNS), focal segmental glomerulosclerosis (FSGS)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ea01b5fc10aa9a96b7b547af294c9e32
https://doi.org/10.3390/ijms22010088

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.